Yahoo Web Search

Search results

1. • Xponance Inc. Sells 939 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

     ETF DAILY NEWS· 5 hours ago

     Xponance Inc. reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 6.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

2. • Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment...

     Morningstar· 1 day ago

     DALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical

3. • 

     I Can See Clearly Now: Eye Care for Seniors Begins at 50 - The Baltimore Times

     Baltimore Times· 7 days ago

     If you can recall the Johnny Nash 70’s chart-topping hit “I Can See Clearly Now” or grew up watching...

4. • Newswise Expert | Carl Awh, American Society of Retina Specialists

     Newswise· 22 hours ago

     Carl Awh, MD (pronounced "Oh") is the President of the Foundation of the American Society of Retina Specialists (ASRS) and Immediate Past President of ASRS. Dr. Awh is an internationally recognized ...

5. • JD Supra: Regeneron v Novartis and Vetter: Walker Process Client Update

     JD Supra· 15 hours ago

     In an appeal that attracted a dozen amici, including the Department of Justice, the Federal Trade Commission, five states, and the District of Columbia, the Second Circuit gave the Walker Process ...

6. • Small Business - Shelby County Reporter | Shelby County Reporter

     The Shelby County Reporter· 2 days ago

     Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight PR Newswire LAS VEGAS, April 24, 2024 The expected launch of potential therapies may increase the Stargardt disease market size in the coming years, assisted by an

7. • 

     Health Care Roundup: Market Talk

     The Wall Street Journal· 4 days ago

     Moreover, its planned launch of aflibercept—for patients living with wet macular degeneration—could be a potentially significant biosimilar opportunity,...

8. • PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC...

     Morningstar· 3 days ago

     Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public

9. • Ocugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan Capital

     ETF DAILY NEWS· 4 days ago

     Ocugen (NASDAQ:OCGN – Get Free Report) had its price objective increased by stock analysts at Chardan Capital from $4.00 to $5.00 in a research report issued on Monday, Benzinga reports. Chardan ...

10. • Brokers Offer Predictions for Unity Biotechnology, Inc.’s FY2024 Earnings (NASDAQ:UBX)

      ETF DAILY NEWS· 6 days ago

      Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Unity Biotechnology in a note issued to investors ...